Insights On Enterprise Solutions
-
Accelerating A Complex Molecule From CLD To cGMP In 12 Months
11/19/2025
Learn how to mitigate technical risk, implement parallel process development, and design custom purification strategies for highly sensitive novel modalities to accelerate to cGMP material.
-
Facility-Fit-Driven Process Development For A Monoclonal Antibody
11/19/2025
See how proactively designing around plant constraints, using high-capacity resins, and leveraging parallel workstreams resulted in a 50% reduction in processing hours and 25% lower costs.
-
Seamless Onshoring From China-Based CDMO
11/19/2025
Successfully mitigate geopolitical risk and maintain supply continuity. Learn how a large-scale manufacturing process was rapidly requalified in eight months to secure a clinical-stage biologic program.
-
Lessons In Scaling Regenerative Medicine Manufacturing With Organogenesis's Patrick Bilbo
11/18/2025
In this episode of "Better Biopharma," Tyler Menichiello is joined by Patrick Bilbo, chief operating officer at Organogenesis, a regenerative medicine company developing and manufacturing advanced wound care products.
-
Advancing Biologics Development With Next-Gen Cell Line Development
11/17/2025
Next-gen CLD utilizes transposase-mediated integration for speed and stability and employs an engineered cell line to enhance ADCC and a high-throughput assay for early glycosylation control.
-
Using Digital Tools In Process Development
11/17/2025
Technology can transform the entire biopharma production process chain. Using integrated process models, machine learning, and genetic algorithms has made production faster and more efficient.
-
How One Biotech Company Is Accelerating The Drug Discovery Workflow
11/14/2025
See how biotech innovation is accelerating drug discovery through AI, miniaturized workflows, and collaborative technologies to reshape how therapies are developed and delivered.
-
Advanced Therapies Going Mainstream: Are We There Yet?
11/14/2025
Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.
-
Industry 5.0: Preparing For The Future Of Biotechnology
11/14/2025
Industry 5.0 represents the next generation of bioproduction—the Adaptive Plant—where human expertise is empowered by AI-enabled insights, autonomous systems, and strategic collaboration.
-
Accelerating Early Phase Biologics From The Clinic To Commercialization
11/13/2025
Strategic planning in early-phase biologics accelerates clinical progress, reduces risk, and lays the groundwork for scalable, compliant manufacturing and successful commercialization.